Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in disability grade Defined as achievement of a specified degree of improvement · patients with Guillain‐Barré syndrome
It is very uncertain whether tripterygium polyglycoside changes improvement in disability grade Defined as achievement of a… compared with corticosteroids (very low certainty).
1 finding from 1 review
Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time from randomisation until discontinuation of ventilation (for those ventilated) · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · patients with Guillain‐Barré syndrome
1 finding from 1 review
Death or disability after 12 months · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
1 finding from 1 review
Improvement in disability grade after 4 weeks · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
1 finding from 1 review
Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome
1 finding from 1 review
Improvement in disability grade Defined as achievement of a specified degree of improvement · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
Eculizumab showed no clear difference in improvement in disability grade Defined as achievement of a… compared with placebo (low certainty).
1 finding from 1 review
Time from randomisation until recovery of unaided walking · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
1 finding from 1 review
no estimate extracted
1 study · 7 participants
Low
Time from randomisation until discontinuation of ventilation (for those ventilated) · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
1 finding from 1 review
Death · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
Eculizumab showed no clear difference in death compared with placebo (low certainty).
1 finding from 1 review
Death or disability after 12 months In the absence of data at 12 months, we report the outcome at 6 months · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
It is very uncertain whether eculizumab changes death or disability after 12 months In the absence of data at 12… compared with placebo (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
Eculizumab showed no clear difference in participants with 1 or more serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Time from randomisation until discontinuation of ventilation (for those ventilated) · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · patients with Guillain‐Barré syndrome
Interferon beta‐1a showed no clear difference in death compared with placebo (low certainty).
1 finding from 1 review
Death or disability after 12 months · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome
1 finding from 1 review